Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 17:14:1385632.
doi: 10.3389/fonc.2024.1385632. eCollection 2024.

MicroRNAs and angiosarcoma: are there promising reports?

Amir Modarresi Chahardehi  1 , Arya Afrooghe  2 , Nikoo Emtiazi  3 , Sajjad Rafiei  4 , Negin Jafarkhanloo Rezaei  5 , Sarvin Dahmardeh  6 , Fatemeh Farz  7 , Zahra Naderi  7   8 , Reza Arefnezhad  9   10 , Hossein Motedayyen  11
Affiliations
Review

MicroRNAs and angiosarcoma: are there promising reports?

Amir Modarresi Chahardehi et al. Front Oncol. .

Abstract

In recent years, microRNAs (miRNAs) have garnered increasing attention for their potential implications in cancer pathogenesis, functioning either as oncogenes or tumor suppressors. Notably, angiosarcoma, along with various other cardiovascular tumors such as lipomas, rhabdomyomas, hemangiomas, and myxomas, has shown variations in the expression of specific miRNA subtypes. A substantial body of evidence underscores the pivotal involvement of miRNAs in the genesis of angiosarcoma and certain cardiovascular tumors. This review aims to delve into the current literature on miRNAs and their prospective applications in cardiovascular malignancies, with a specific focus on angiosarcoma. It comprehensively covers diagnostic methods, prognostic evaluations, and potential treatments while providing a recapitulation of angiosarcoma's risk factors and molecular pathogenesis, with an emphasis on the role of miRNAs. These insights can serve as the groundwork for designing randomized control trials, ultimately facilitating the translation of these findings into clinical applications. Moving forward, it is imperative for studies to thoroughly scrutinize the advantages and disadvantages of miRNAs compared to current diagnostic and prognostic approaches in angiosarcoma and other cardiovascular tumors. Closing these knowledge gaps will be crucial for harnessing the full potential of miRNAs in the realm of angiosarcoma and cardiovascular tumor research.

Keywords: angiosarcoma; cancer; cardiovascular tumor; microRNA; oncogenesis; tumor suppressor.

PubMed Disclaimer

Conflict of interest statement

Author AM was employed by Kimia Andisheh Teb Medical and Molecular Research Laboratory Co. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Several risk factors for angiosarcoma (adapted from Ni et al. (33) (33).
Figure 2
Figure 2
Roles of oncogenic and tumor suppressive microRNAs [adapted from Hata et al. (2015)] (92).
Figure 3
Figure 3
MiRNAs involved in angiosarcoma.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Motedayyen H, Ghotloo S, Saffari M, Sattari M, Amid R. Evaluation of microRNA-146a and its targets in gingival tissues of patients with chronic periodontitis. J periodontol. (2015) 86:1380–5. doi: 10.1902/jop.2015.150319 - DOI - PubMed
    1. Yang F, Ning Z, Ma L, Liu W, Shao C, Shu Y, et al. . Exosomal miRNAs and miRNA dysregulation in cancer-associated fibroblasts. Mol Cancer. (2017) 16:148. doi: 10.1186/s12943-017-0718-4 - DOI - PMC - PubMed
    1. Turk A, Calin GA, Kunej T. MicroRNAs in leukemias: A clinically annotated compendium. Int J Mol Sci. (2022) 23:1–16. doi: 10.3390/ijms23073469 - DOI - PMC - PubMed
    1. Goleij P, Babamohamadi M, Rezaee A, Sanaye PM, Tabari MAK, Sadreddini S, et al. . Types of RNA therapeutics. Prog Mol Biol Trans Sci. (2024) 203:41–63. doi: 10.1016/bs.pmbts.2023.12.022 - DOI - PubMed
    1. Smolarz B, Durczynski A, Romanowicz H, Szyllo K, Hogendorf P. miRNAs in cancer (Review of literature). Int J Mol Sci. (2022) 23:1–18. doi: 10.3390/ijms23052805 - DOI - PMC - PubMed

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

LinkOut - more resources

-